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Abstract: Background: Relapsing-Remitting (RRMS) is the most common Multiple Sclerosis 
disease course. Interferon regulatory factor 3 (IRF3) as major regulators of immune system genes 
plays a critical role in the activation of type I interferons promoters, in particular IFNβ promoter. 
Hence we aimed to evaluate the expression rate of IRF3 in RRMS patients under different type of 
IFNβ treatment. Material and methods: In the present study total of 100 subjects participated. Blood 
samples of 25 patients with RRMS newly diagnosed who have not been treated with interferon 
components, 25 patients with RRMS treated with Interferon beta-1α (B1a), 25 patients with RRMS 
treated with Interferon beta-1β (B1b) and 25 control samples were collected. The samples were 
transferred at standard conditions to the Cellular and Molecular Research Center of Shahrekord 
University of Medical Sciences, RNA was extracted and converted to cDNA. To evaluate the 
expression of IRF3 the Real-Time PCR method using SYBR Green dye was done. The level of gene 
expression was measured by a comparative threshold cycle formula. The obtained data were 
analyzed using SPSS v15 software. Results: In the study we compared the IRF3 mRNA expression 
of all subjects in association with gender, which no significant difference was seen (P > 0.05). Also 
assessment of the gene mRNA level in study groups revealed that the B1b, B1a and new case group 
had the lowest expression respectively. Moreover, comparison of the mRNA level between new case 
and B1b groups showed remarkable difference (P < 0.05). According to age and sex factors, no 
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remarkable differences between study groups were seen (P > 0.05). Conclusion: Perhaps the IFNβ 
recombinants decreases the IRF3 expression as a negative feedback mechanism. Overall the data 
reported here, supports the previous studies in important role of IRF3 in autoimmune inflammatory 
disease of CNS and Multiple Sclerosis. 
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1. Introduction 
Multiple sclerosis (MS) is a chronic immune-mediated disorder of central nervous system 
resulting from both genetic and environmental factors. The MS characterized by inflammation and 
neurodegeneration with significant social and economic impact. It usually affects young individuals 
between 20 to 40 years old which about 60% of cases are females [1]. The worldwide prevalence of 
MS varies in different geographical regions and has increased in last decades. Global estimation 
revealed that the disease affects more than 2.5 million people. In Iran the MS has a growing 
prevalence rate (51.52 per 100,000) [2]. 
The dominant hypothesis in MS pathophysiology considers an important role for auto-reactive 
T cells in which these cells leading series of events such as increment of pro-inflammatory cytokines, 
adhesion molecules, metalloproteinases, blood-brain barrier damage and as a result infiltration of 
immune cells to CNS [3,4]. According to international panel of neurologists the MS has four distinct 
clinical patterns, which the most common subtype is the Relapsing-Remitting MS (RRMS) that 
accounts for approximate 85% of cases. In this form, an acute phase followed up by partial or full 
recovery [5]. 
IRF3 as a member of interferon regulatory factor family is one of the major regulators of 
immune system genes with well-known role in antiviral immunity [6]. Pathogens or synthetic ligands 
stimulate pattern recognition receptors that resulting in phosphorylation of IRF-3. Afterward the 
factor translocates to nucleus in order to induction of Type I interferons transcription and results in 
the activation of type I interferons promoters, in particular IFNβ promoter. Secreted IFNβ through 
JAK-STAT signaling pathway induces IRF7 that as a positive feedback loop amplifies multiple 
subtype of type I IFN [6–8]. 
Of type I interferons, beta interferons are the first line of disease-modification treatments (DMTs) 
that have proved efficacy for treatment of RRMS patients. Recombinant IFNβ has 3 different 
pharmaceutical formula: IFNβ-1a, 6 MIU (30 μg) (Avonex), IFNβ-1a (22 and 44 μg) (Rebif), and 
IFNβ-1b, 8 MIU (250 μg) (Betaferon). Although the precise mechanism of action of these 
immunomodulatory drugs in MS has not been clarified, but it seems that generally they shift 
cytokine profile from pro-inflammatory to anti-inflammatory [9]. A baseline level of IFN for 
maintain type I IFN signaling is needed. High percentage of MS patients have low serum IFNs, so 
this may be the reason of low responses to IFNβ therapy [10]. 
Limited studies investigated the role of IRFs in multiple sclerosis. According to earlier studies 
IRF-3 modulates neuroinflammatory responses [11]. Tarassishin et al. investigated the critical role of 
IFR-3 in microglia phenotype change in CNS, the results showed that IRF3-overexpressing microglia 
upregulate key anti-inflammatory cytokines and downregulate proinflammatory cytokines [6].  
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Touil et al. reported that suppression of RRMS in murine model of MS by polyinosinc-polycytidylic  
acid (P I:C) is associated with the induction of IFNβ. Their data indicated that P I:C exerts its  
anti-inflammatory effects through TLR3 stimulation followed by translocation of IRF3 that resulted 
in IFNβ production and increased level of TNF-α [12]. 
Considering previous studies about the central role of IRF3 in signal transduction cascades of 
type I IFN and immune-mediated disease, we have decided to evaluate the expression rate of IRF3 in 
RRMS patients under different type of IFNβ treatment. 
2. Material and methods 
2.1. Subjects 
This case-control study was conducted on the patients referring MS Center and Kashani 
Hospital, Shahrekord, Iran from 2017 to 2018. A total of 100 individuals (21 males, 79 females) 
participated in the research including 25 new cases of RRMS patient, 25 RRMS patients treated with 
IFNβ-1a (B1a), 25 RRMS patients treated with IFNβ-1b (B1b) and 25 control subjects. The inclusion 
criteria for study group were as follows: meeting the 2017 revisions of the “McDonald” Criteria [13] for 
definite diagnosing of MS, a disease course featuring relapses and remissions. Also the exclusion 
criteria for this group were as follows: history of any autoimmune disease, chronic infection, and use 
immunomodulatory therapy or immunosuppressive drugs. Study was approved by the ethics 
committee of Shahrekord University of Medical Sciences and all patients provided written informed 
consent. 
2.2. Total RNA extraction and cDNA synthetize  
All participants’ blood samples (3ml) were collected in EDTA tube. Total RNA from peripheral 
blood cells was extracted using an RNeasy Mini kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s recommendations. Briefly the blood was incubated with erythrocyte lysing buffer. 
Then cloudy suspension was washed and centrifuged at 400 g for 10 minutes. The cellular pellet of 
leukocytes was lysed with RTL solution. The cell emulsion was loaded on spin columns and 
centrifuged. Later 70% ethanol added to the homogenized lysate and pipetted into new spin columns 
and centrifuged. On the next step the solution was washed with DW. Then the RPE buffer added to 
column and centrifuged at high speed (14,000 RPM). At the end the spin column transferred to 
microcentrifuge tube and 30–50 μL of RNase-free water were added directly to the membrane and 
centrifuged. Extracted RNA were treated with DNase and reverse-transcribed to cDNA, according to 
the Transcription kit instructions (QIAGEN, Germany). 
2.3. Real-time quantitative PCR 
To evaluate the expression level of IRF3 in study groups, quantitative real-time PCR analyses 
were performed using specific designed primers and SYBER Green PCR Master Mix (QIAGEN, 
Hilden, Germany) in Corbett 3000 (Corbett, Sydney, Australia) detection system. The sense and  
anti-sense primers for IRF3 were as follows: sense GGACGCTCACCACGCTAT anti-sense: 
GCACAACCTTGACCATCACGA. 1 μL of synthesized cDNA products were added into PCR 
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reaction mix containing 5 μL SYBR Green master mix, 0.5 μL of each primer and 3μl of nuclease-
free water. The PCR process was programmed as 94 °C for 45 seconds (Taq polymerase activation), 
94 °C for 15 seconds (denaturation), 60 °C for 20 seconds (annealing), and 72 °C for 25  
seconds (extension). Samples were run in triplicate and GAPDH gene used as an endogenous control. 
Expression levels of target genes were calculated using a comparative threshold cycle formula. That 
is, the expression level of target genes to reference genes in treated samples compared to the normal 
controls was calculated through 2-ΔΔCT formula: 
ΔΔCT = Δ(CT target gene − CT control group) − Δ(CT target gene − CT GAPDH)     (1) 
2.4. Statistical analysis 
Data of mRNA expression were analyzed by SPSS v15 software. Relative expression of IRF3 
gene between patient groups calculated using the Student’s t-test and Chi-square test. Data were 
reported as mean ±SD. A p value of less than 0.05 was considered statistically significant. 
3. Results 
3.1. Demographic data of participants 
In this research age and sex ratio distribution showed that from 100 subjects 21% were  
male (mean age: 32.05 ± 9.9 years) and 79% were female (mean age: 30.3 ± 7.3 years). In the present 
study 25 age- and sex-matched healthy control subjects and 75 patients were recruited. Our 75 
RRMS patients diagnosed according to the revised McDonald criteria[13], consist of 18 males and 
57 females (Table 1). Comparison of subjects mean age according to sex ratio, did not show any 
significant difference (P > 0.05). Also evaluation of patients groups mean age showed no significant 
differences compare to control group (P > 0.05). The age and sex distribution in our patients and 
control groups were normalized. 
Table1. Demographical and clinical characteristics of participants. 
Groups Number Age (mean ± SD) Female / Male 
Control 25 30.4 ± 7.5 22 / 3 
New case 25 27.3 ± 7.5 18 / 7 
B1a 25 33.9 ± 8.4 18 / 7 
B1b 25 31.6 ± 7.2 21 / 4 
3.2. Lower IRF3 gene expression in RRMS patient groups 
The mRNA expression of IRF3 was evaluated by real-time PCR method in study groups. The 
mean of IRF3 gene expression in all subjects (100) was 3.75 ± 3.19. Also comparison of the mRNA 
expression of all subjects in association with gender, showed no significant difference (P > 0.05). 
The IRF3 mRNA level was assessed in study groups. The results revealed that in comparison to 
control group, the B1a, B1b and new case groups had lower mRNA expression respectively. IRF3 
mRNA level in B1b and B1a groups compared to control group was remarkably lower. Moreover, 
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the gene expression in new case group showed significant difference with B1b group. In comparison 
of IRF3 expression level in B1a group to new case and B1b groups, no remarkable difference was 
seen (Figure 1). In this research according to age and sex factors, no remarkable differences between 
study groups were seen. 
 
Figure 1. The relative expression of IRF3 in different study groups evaluated by by Real-
time RT-qPCR method. Samples were run in triplicate and GAPDH gene used as an 
endogenous control. The mRNA expression of target gene in all study groups were 
calculated using the 2-ΔΔCT formula. ΔΔCT = Δ(CT target gene − CT control group) − Δ(CT target gene 
− CT GAPDH). The mean expression levels of IRF3 was assessed in study groups. The 
results revealed that the control group had the most mRNA expression and the new case, 
B1a and B1b groups had lower expression respectively. *** Indicates a significance level 
below 0. **Indicates a significance level below 0.05. 
4. Discussion 
The exact cause of MS disease has not been clearly clarified yet, however genetic recognized as 
the major contributor factor. Beside genetics, nucleic and mitochondrial DNA defects, Viral 
infections, hypoxia, oxidative stress, lack of light or low levels of vitamin D and increased 
macrophages (microglia) and lymphocytes in the brain may cause the development of MS [14]. In 
the present study we evaluated the IRF3 gene expression in RRMS patients compared with controls. 
In the present study, 21% of all subjects were male and 79% were female, and the average age 
of the patients did not show a significant difference in association with their sex. The mean age 
evaluation revealed that B1b and new case group, respectively, had the highest and lowest mean age. 
There was a significant difference between the two groups regarding age factor. Pajouh et al. 
identified the frequency and characteristics of dysphagia in multiple sclerosis patients of Khuzestan 
M.S society. Their study consisted of 21 male and 84 female with mean age of 33.89 ± 8.56 years [15]. 
The results of our study in relation to the sex ratio and mean age of the patients was in consistent 
with Pajouh et al. study. Also in a research by Poorjavad et al. the association factors with 
swallowing disorders in patients with multiple sclerosis was assessed. In their research 19.8% of MS 
patients were male and 80.2% were female, and the mean age of subjects were 34 ± 9.3 years [16]. 
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Our study results in relation to age and sex ratio was in line with their study. Also present study 
indicates higher prevalence of MS in females than in males with more frequent develop of RRMS in 
females. It seems that differences in immune and nervous system between women and men as a 
consequence of gonadal hormones effects, also genetic and life style affects the MS incidence among 
women. 
The results of present study showed that IRF3 mRNA level in B1b, B1a and new case groups 
were respectively lower compared to control group Schultz et al. evaluated the role of IRF3 and IRF7 
deficiencies in the mice with Sindbis virus (alpha virus that cause encephalomyelitis). The results 
revealed that IRF3-/- mice compared to wild type mice developed persistent neurological deficits, 
more inflammation in spinal cord and higher levels of IFNγ mRNAs [17]. Another study by 
Tarassishin et al. explored the consequence of adenovirus-mediated IRF3 gene transfer (Ad-IRF3) in 
primary human astrocytes. They showed that IRF3 transgene expression suppresses proinflammatory 
cytokine gene expression upon challenge with IL-1/IFNγ and alters astrocyte activation phenotype 
from a proinflammatory to an anti-inflammatory one, akin to an M1 to M2 switch in macrophages. 
Also Ad-IRF3 suppressed the expression of microRNA-155 and its star-form partner miR-155*and 
immunoregulatory miRNAs which highly expressed in multiple sclerosis lesions [18]. As we 
mentioned different IFNβ compounds are used as immunoregulators in MS patients. According to 
Feng et al. study cultured mononuclear immune cells of MS patients with active clinical progression 
are resistant to IFNβ and operation of responses needed a high doses of IFN in MS patients’ active 
clinical progression [19]. Also in vivo study by Panitch et al. revealed that IFNβ therapy in early 
RRMS patients than those with later stage of MS is more effective [20]. Our results along with this 
studies showed difference in IRF3 gene expression in IFNβ treated groups. According to our finding 
time passing and progression of disease could alter the IRF3 gene expression. Also lower levels of 
IRF3 mRNA expression in IFNβ treated groups compared to new case group were seen. These 
findings may show that the interferon beta component exert their effects through alternation of IRF3 
signaling pathways [20]. It appears that this drugs decrease the production and activity of IL-1 
cytokine and therefore reduce inflammatory responses in CNS. The exact mechanism of action of 
IFNβ recombinants in altering IL-1 have not been fully elucidated but some studies shown that this 
drugs through their effect on Toll-Like Receptors (TLRs) and signaling molecules led to a decrease 
in IL-1 production [21] and also effects on NLRs results in decreased activity of this cytokine [22]. 
In a study by Downer et al the effects of a synthetic cannabinoid on TLR signaling, with particular 
focus on the molecular mechanism controlling the induction of IFNβ were assessed. They introduce 
the synthetic cannabinoid, R(+)WIN55,212-2 as a novel regulator of TLR3 and TLR4 signaling by 
mechanism of inhibiting the pro-inflammatory signaling axis that triggered by TLR3 and TLR4, 
whereas selectively augmenting TLR3-induced activation of IFN regulatory factor 3 (IRF3) and 
expression of IFNβ. Furthermore that cells from MS patients were especially sensitive to 
R(+)WIN55,212-2 in terms of increased expression of endogenous IFNβ and this strongly indicated 
this mechanism has relevance to treatment of MS [23]. In the present study the IRF3 expression in 
new case group compared to control group was significantly lower. It seems that immune system 
responses in the early stage of the disease in a negative feedback suppresses the IRF3 expression in 
order to regulate the inflammatory conditions. This finding is in consistence with previous studies in 
effectiveness of early MS diagnosis and treatment in improvement of mortality [24]. Because the 
immune system at an early stage tries to trigger inhibitory mechanisms for modulating inflammatory 
factors. 
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Recent study reported a crucial role of IRF3 in development of TH17 responses and induction 
of EAE. So according to our findings probably recombinant IFNβ products exert their effects through 
lowering the IRF3 factor that followed by decreased inflammatory responses. Overall our data 
supports the important role of IRF3 in immunoregulation and immune-mediated disease and further 
study is needed to evaluate the alternation of gene expression of other proteins in IRF3 signaling. 
5. Conclusion 
Determination of IRF3 mRNA level in blood of RRMS patients showed a reduction of the gene 
expression in new case, B1a treated and B1b groups respectively compared to control group. Perhaps 
the IFNβ recombinants decreases the IRF3 expression as a negative feedback mechanism. Overall 
the data reported here, supports the previous studies in important role of IRF3 in autoimmune 
inflammatory disease of CNS and Multiple Sclerosis. 
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